KLP Kapitalforvaltning AS Trims Stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Key Points

• KLP Kapitalforvaltning AS reduced its stake in LeMaitre Vascular by 56.8%, selling 5,000 shares and ending up with 3,800 shares worth $319,000.
• Insider trading activity includes CEO George W. Lemaitre selling 4,399 shares valued at approximately $374,355, resulting in a 0.24% decrease in his ownership.
• LeMaitre Vascular reported an EPS of $0.48 for the last quarter, falling short of the consensus estimate of $0.50, despite revenues increasing by 12% year-over-year.

KLP Kapitalforvaltning AS trimmed its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 56.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,800 shares of the medical instruments supplier's stock after selling 5,000 shares during the quarter. KLP Kapitalforvaltning AS's holdings in LeMaitre Vascular were worth $319,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Principal Financial Group Inc. grew its stake in shares of LeMaitre Vascular by 3.0% during the 1st quarter. Principal Financial Group Inc. now owns 111,865 shares of the medical instruments supplier's stock worth $9,385,000 after acquiring an additional 3,248 shares during the period. Invesco Ltd. grew its stake in shares of LeMaitre Vascular by 50.5% during the 4th quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier's stock worth $16,124,000 after acquiring an additional 58,720 shares during the period. Compass Planning Associates Inc grew its stake in shares of LeMaitre Vascular by 91.4% during the 1st quarter. Compass Planning Associates Inc now owns 11,776 shares of the medical instruments supplier's stock worth $988,000 after acquiring an additional 5,623 shares during the period. Johnson Investment Counsel Inc. grew its stake in shares of LeMaitre Vascular by 34.8% during the 1st quarter. Johnson Investment Counsel Inc. now owns 29,428 shares of the medical instruments supplier's stock worth $2,469,000 after acquiring an additional 7,603 shares during the period. Finally, Consolidated Planning Corp bought a new position in shares of LeMaitre Vascular during the 1st quarter worth $947,000. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Stock Up 3.0%

Shares of LMAT stock traded up $2.45 during mid-day trading on Monday, hitting $83.49. The company's stock had a trading volume of 46,110 shares, compared to its average volume of 185,820. LeMaitre Vascular, Inc. has a 52-week low of $71.42 and a 52-week high of $109.58. The business has a 50-day moving average price of $82.52 and a 200 day moving average price of $86.79. The company has a debt-to-equity ratio of 0.48, a quick ratio of 13.83 and a current ratio of 16.49. The stock has a market cap of $1.89 billion, a price-to-earnings ratio of 42.17, a PEG ratio of 2.14 and a beta of 0.79.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). The firm had revenue of $59.87 million for the quarter, compared to analysts' expectations of $57.61 million. LeMaitre Vascular had a net margin of 19.96% and a return on equity of 13.53%. The firm's revenue was up 12.0% compared to the same quarter last year. During the same quarter last year, the company posted $0.44 EPS. Research analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

Insider Buying and Selling at LeMaitre Vascular

In related news, CEO George W. Lemaitre sold 76,868 shares of the stock in a transaction that occurred on Monday, May 19th. The stock was sold at an average price of $85.79, for a total transaction of $6,594,505.72. Following the completion of the transaction, the chief executive officer directly owned 1,796,783 shares of the company's stock, valued at approximately $154,146,013.57. This represents a 4.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 100,000 shares of company stock valued at $8,556,857 over the last three months. Corporate insiders own 9.50% of the company's stock.

Wall Street Analyst Weigh In

Separately, Barrington Research restated a "market perform" rating on shares of LeMaitre Vascular in a research note on Tuesday, July 22nd. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $97.83.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.